Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2001

View Archived Issues

Indatraline/buprenorphine therapy reduces speedball use in monkeys

Preliminary results reported for pilot study of Titan's Spheramine in advanced Parkinson's disease

MBI-594AN phase II clinical trial for acne completes enrollment

Arrhythmogenicity of nesiritide and dobutamine compared in CHF patients

New tablet form of Rapamune for kidney transplants now available in the U.S.

Enrollment begins for phase II trial of Metastat in HIV-related Kaposi's sarcoma

FDA accepts resubmission to the BLA for Zevalin

PPI rabeprazole and thioester derivative inhibit motility and growth of CRHP

IND application submitted for Product R

Phase I trial of Triapine in combination with gemcitabine set to begin

ZD-6021, AstraZeneca's tachykinin receptor antagonist, characterized

Interaction between parkin and alpha-synuclein in Parkinson's disease revealed

Low vitamin B12 and folate levels may increase risk of AD

Oral paclitaxel shows promising results in phase II lung cancer trials

Phase I/II trials evaluating PI-88 for cancer set to begin

C&C Research reports compounds useful as antiestrogenic agents

Pfizer patents novel protein kinase inhibitors

Muscarinic antagonists and agonists reported by Advanced Medicine

Phase II trial planned for Aphton's antigastrin-targeted therapy in lung cancer patients

Mitsubishi-Tokyo Pharmaceuticals describes new Alzheimer's disease compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...